| 2922.49.40 | 15 | l-Aspartic acid | kg | | | |
| 2922.49.40 | 50 | Other | kg | | | |
| 2922.49.60 | 00 | Other: | | | | |
| 2922.49.60 | 00 | 3-Aminocrotonic acid, methyl ester; and ¡é/- α-Amino-1,4-cyclohexadiene-1- acetic acid | kg | Free | | 25% |
| 2922.49.80 | 00 | Other | kg | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 25% |
| 2922.50 | | Amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function: | | | | |
| 2922.50.07 | 00 | Aromatic: | | | | |
| 2922.50.07 | 00 | 3,4-Diaminophenetole dihydrogen sulfate; 2-Nitro-5-[(2,3-dihydroxy)propoxy]-¡é/methylaniline; 2-Nitro-5-(2-hydroxyethoxy)-N-methylaniline; 4-(2-Hydroethoxy)-1,3-phenylenediamine dihydrochloride; 3-Methoxy-4-[(2-hydroxyethyl)amino]nitro- benzene; 4-[(2-Hydroxyethyl)amino]-3-nitrophenol; and ¡é/- α-Amino-4-hydroxybenzeneacetic acid (d(-)-p-Hydroxyphenylglycine) | kg | Free | | 15.4¡é/kg + 50% |
| 2922.50.10 | 00 | dl-3-(3,4-Dihydroxyphenyl)alanine; N-Ethyl-N-(2-methoxycarbonylethyl)aniline; dl-Phenylephrine base; and Carbonic acid, methyl ester, diester with 2,2'-(m-tolylamino)diethanol (Toluidine carbonate) | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¡é/kg + 39% |
| 2922.50.11 | 00 | Salts of d(-)-p-Hydroxyphenylglycine (¡é/- α-Amino-4-hydroxybenzeneacetic acid) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX,P) 0.2¡é/kg + 3.1% (SG) | 15.4¡é/kg + 50% |
| 2922.50.13 | 00 | Other: | | | | |
| 2922.50.13 | 00 | Drugs: | | | | |
| 2922.50.13 | 00 | Isoetharine hydrochloride; Isoxsuprine hydrochloride; Nylidrin hydrochloride; Phenylephrine hydrochloride; Salbutamol (Albuterol); and Terbutaline sulfate | kg | Free | | 15.4¡é/kg + 47% |
| 2922.50.14 | 00 | Other: | | | | |
| 2922.50.14 | 00 | Cardiovascular drugs | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¡é/kg + 65% |
| 2922.50.17 | 00 | Dermatological agents and local anesthetics | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¡é/kg + 51.5% |
| 2922.50.19 | 00 | Guaiacol derivatives | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 15.4¡é/kg + 79% |
| 2922.50.25 | 00 | Other | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¡é/kg + 82% |
| 2922.50.35 | 00 | Other: | | | | |
| 2922.50.35 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¡é/kg + 50% |
| 2922.50.40 | 00 | Other | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 0.2¡é/kg + 3.1% (SG) | 15.4¡é/kg + 50% |
| 2922.50.50 | 00 | Other | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 30.5% |
| 2923 | | Quaternary ammonium salts and hydroxides; lecithins and other phosphoaminolipids, whether or not chemically defined: | | | | |
| 2923.20 | | Lecithins and other phosphoaminolipids: | | | | |
| 2923.20.10 | 00 | Purified egg phospholipids, pharmaceutical grade meeting requirements of the U.S. Food and Drug Administration, for use in intravenous fat emulsion | kg | Free | | 16.5¡é/kg + 30% |
